A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
NCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardNCT 06929663 Brief Summary This is an first-in-human, Phase I clinical study…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05410145 Brief Summary This is a first-in-human (FIH), multicenter, open-label, dose-escalation,…
Read more arrow_forwardNCT 06179160 Brief Summary This study is conducted to determine the safety…
Read more arrow_forwardNCT 06710847 Brief Summary Solid tumours are abnormal lumps of tissue that…
Read more arrow_forwardNCT 06597721 Brief Summary Adcendo ApS is conducting a phase 1 study…
Read more arrow_forward